Parkinson Disease Drug Market Size, Share, Growth, and Industry Analysis, By Type (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, Others), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast to 2035
Table of Content
1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Parkinson Disease Drug Market Size
1.3 Market Segmentation
1.4 Regulatory Environment
2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Parkinson Disease Drug Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Parkinson Disease Drug Business Mode and Production Process
2.3.1 Parkinson Disease Drug Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Parkinson Disease Drug Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Parkinson Disease Drug
2.4.2 Raw Material Cost of Parkinson Disease Drug
2.4.3 Labor Cost of Parkinson Disease Drug
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis
3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War
4 Market Competitive Landscape
4.1 Global Parkinson Disease Drug Revenue and Market Share by Manufacturer (2020-2026)
4.2 Global Parkinson Disease Drug Sales Volume and Market Share by Manufacturer (2020-2026)
4.3 Global Parkinson Disease Drug Price by Manufacturer (2020-2026)
4.4 Parkinson Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Parkinson Disease Drug, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Parkinson Disease Drug, Product Offered and Application
4.7 Parkinson Disease Drug Market Competitive Situation and Trends
4.7.1 Parkinson Disease Drug Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Parkinson Disease Drug Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans
5 Global Parkinson Disease Drug Market Historical Development by Geographic Region (2020-2026)
5.1 Global Parkinson Disease Drug Market Historical Sales Volume by Geographic Region (2020-2026)
5.2 Global Parkinson Disease Drug Market Historical Revenue by Geographic Region (2020-2026)
5.3 North America Parkinson Disease Drug Market Status by Country (2020-2026)
5.3.1 North America Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.3.2 North America Parkinson Disease Drug Revenue by Country (2020-2026)
5.3.3 United States Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.3.4 Canada Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4 Europe Parkinson Disease Drug Market Status by Country (2020-2026)
5.4.1 Europe Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.4.2 Europe Parkinson Disease Drug Revenue by Country (2020-2026)
5.4.3 Germany Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.4 France Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.5 United Kingdom Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.6 Spain Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.7 Russia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.8 Poland Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5 Asia Pacific Parkinson Disease Drug Market Status by Country (2020-2026)
5.5.1 Asia Pacific Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.5.2 Asia Pacific Parkinson Disease Drug Revenue by Country (2020-2026)
5.5.3 China Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.4 Japan Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.5 South Korea Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.6 Southeast Asia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.7 India Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.8 Australia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.6 Latin America Parkinson Disease Drug Market Status by Country (2020-2026)
5.6.1 Latin America Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.6.2 Latin America Parkinson Disease Drug Revenue by Country (2020-2026)
5.6.3 Mexico Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.6.4 Brazil Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.7 Middle East and Africa Parkinson Disease Drug Market Status by Country (2020-2026)
5.7.1 Middle East and Africa Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.7.2 Middle East and Africa Parkinson Disease Drug Revenue by Country (2020-2026)
5.7.3 GCC Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.7.4 South Africa Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
6 Global Parkinson Disease Drug Market Historical Development by Product Type (2020-2026)
6.1 Parkinson Disease Drug Definition by Type
6.2 Global Parkinson Disease Drug Historical Sales Volume by Product Type (2020-2026)
6.3 Global Parkinson Disease Drug Historical Revenue by Product Type (2020-2026)
6.4 Global Parkinson Disease Drug Historical Price by Product Type (2020-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2020-2026)
6.5.1 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Decarboxylase Inhibitors (2020-2026)
6.5.2 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Dopamine Agonists (2020-2026)
6.5.3 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Monoamine Oxidase Type B (MAO-B) Inhibitor (2020-2026)
6.5.4 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Catechol-O-Methyltransferase (COMT) Inhibitors (2020-2026)
6.5.5 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Others (2020-2026)
7 Global Parkinson Disease Drug Market Historical Development by End User (2020-2026)
7.1 Downstream Market Overview
7.2 Global Parkinson Disease Drug Historical Sales Volume by End User (2020-2026)
7.3 Global Parkinson Disease Drug Historical Revenue by End User (2020-2026)
7.4 Global Parkinson Disease Drug Historical Price by End User (2020-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2020-2026)
7.5.1 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Hospital Pharmacy (2020-2026)
7.5.2 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Retail Pharmacy (2020-2026)
7.5.3 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Online Pharmacy (2020-2026)
8 Leading Companies Profiles
8.1 Sanofi S.A.
8.1.1 Sanofi S.A. Corporation Information
8.1.2 Sanofi S.A. - Parkinson Disease Drug Product Portfolio and Specification
8.1.3 Sanofi S.A. Performance Analysis (2020-2026)
8.1.4 Sanofi S.A. Business and Markets Served
8.1.5 Sanofi S.A. Recent Developments
8.2 Lundbeck A/S
8.2.1 Lundbeck A/S Corporation Information
8.2.2 Lundbeck A/S - Parkinson Disease Drug Product Portfolio and Specification
8.2.3 Lundbeck A/S Performance Analysis (2020-2026)
8.2.4 Lundbeck A/S Business and Markets Served
8.2.5 Lundbeck A/S Recent Developments
8.3 Impax Laboratories, Inc.
8.3.1 Impax Laboratories, Inc. Corporation Information
8.3.2 Impax Laboratories, Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.3.3 Impax Laboratories, Inc. Performance Analysis (2020-2026)
8.3.4 Impax Laboratories, Inc. Business and Markets Served
8.3.5 Impax Laboratories, Inc. Recent Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Teva Pharmaceutical Industries Ltd. Corporation Information
8.4.2 Teva Pharmaceutical Industries Ltd. - Parkinson Disease Drug Product Portfolio and Specification
8.4.3 Teva Pharmaceutical Industries Ltd. Performance Analysis (2020-2026)
8.4.4 Teva Pharmaceutical Industries Ltd. Business and Markets Served
8.4.5 Teva Pharmaceutical Industries Ltd. Recent Developments
8.5 GlaxoSmithKline plc
8.5.1 GlaxoSmithKline plc Corporation Information
8.5.2 GlaxoSmithKline plc - Parkinson Disease Drug Product Portfolio and Specification
8.5.3 GlaxoSmithKline plc Performance Analysis (2020-2026)
8.5.4 GlaxoSmithKline plc Business and Markets Served
8.5.5 GlaxoSmithKline plc Recent Developments
8.6 C.H. Boehringer Sohn AG & Ko. KG
8.6.1 C.H. Boehringer Sohn AG & Ko. KG Corporation Information
8.6.2 C.H. Boehringer Sohn AG & Ko. KG - Parkinson Disease Drug Product Portfolio and Specification
8.6.3 C.H. Boehringer Sohn AG & Ko. KG Performance Analysis (2020-2026)
8.6.4 C.H. Boehringer Sohn AG & Ko. KG Business and Markets Served
8.6.5 C.H. Boehringer Sohn AG & Ko. KG Recent Developments
8.7 ACADIA Pharmaceuticals Inc.
8.7.1 ACADIA Pharmaceuticals Inc. Corporation Information
8.7.2 ACADIA Pharmaceuticals Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.7.3 ACADIA Pharmaceuticals Inc. Performance Analysis (2020-2026)
8.7.4 ACADIA Pharmaceuticals Inc. Business and Markets Served
8.7.5 ACADIA Pharmaceuticals Inc. Recent Developments
8.8 Merck & Co., Inc.
8.8.1 Merck & Co., Inc. Corporation Information
8.8.2 Merck & Co., Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.8.3 Merck & Co., Inc. Performance Analysis (2020-2026)
8.8.4 Merck & Co., Inc. Business and Markets Served
8.8.5 Merck & Co., Inc. Recent Developments
8.9 Medtronic plc
8.9.1 Medtronic plc Corporation Information
8.9.2 Medtronic plc - Parkinson Disease Drug Product Portfolio and Specification
8.9.3 Medtronic plc Performance Analysis (2020-2026)
8.9.4 Medtronic plc Business and Markets Served
8.9.5 Medtronic plc Recent Developments
8.10 Abbvie Inc
8.10.1 Abbvie Inc Corporation Information
8.10.2 Abbvie Inc - Parkinson Disease Drug Product Portfolio and Specification
8.10.3 Abbvie Inc Performance Analysis (2020-2026)
8.10.4 Abbvie Inc Business and Markets Served
8.10.5 Abbvie Inc Recent Developments
8.11 Homann-La Roche Ltd
8.11.1 Homann-La Roche Ltd Corporation Information
8.11.2 Homann-La Roche Ltd - Parkinson Disease Drug Product Portfolio and Specification
8.11.3 Homann-La Roche Ltd Performance Analysis (2020-2026)
8.11.4 Homann-La Roche Ltd Business and Markets Served
8.11.5 Homann-La Roche Ltd Recent Developments
8.12 Pzer, Inc.
8.12.1 Pzer, Inc. Corporation Information
8.12.2 Pzer, Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.12.3 Pzer, Inc. Performance Analysis (2020-2026)
8.12.4 Pzer, Inc. Business and Markets Served
8.12.5 Pzer, Inc. Recent Developments
8.13 F. Hoffmann-La Roche AG
8.13.1 F. Hoffmann-La Roche AG Corporation Information
8.13.2 F. Hoffmann-La Roche AG - Parkinson Disease Drug Product Portfolio and Specification
8.13.3 F. Hoffmann-La Roche AG Performance Analysis (2020-2026)
8.13.4 F. Hoffmann-La Roche AG Business and Markets Served
8.13.5 F. Hoffmann-La Roche AG Recent Developments
8.14 Vertical Pharmaceuticals, LLC
8.14.1 Vertical Pharmaceuticals, LLC Corporation Information
8.14.2 Vertical Pharmaceuticals, LLC - Parkinson Disease Drug Product Portfolio and Specification
8.14.3 Vertical Pharmaceuticals, LLC Performance Analysis (2020-2026)
8.14.4 Vertical Pharmaceuticals, LLC Business and Markets Served
8.14.5 Vertical Pharmaceuticals, LLC Recent Developments
8.15 Orion Pharma
8.15.1 Orion Pharma Corporation Information
8.15.2 Orion Pharma - Parkinson Disease Drug Product Portfolio and Specification
8.15.3 Orion Pharma Performance Analysis (2020-2026)
8.15.4 Orion Pharma Business and Markets Served
8.15.5 Orion Pharma Recent Developments
8.16 UCB S.A
8.16.1 UCB S.A Corporation Information
8.16.2 UCB S.A - Parkinson Disease Drug Product Portfolio and Specification
8.16.3 UCB S.A Performance Analysis (2020-2026)
8.16.4 UCB S.A Business and Markets Served
8.16.5 UCB S.A Recent Developments
8.17 Novartis AG
8.17.1 Novartis AG Corporation Information
8.17.2 Novartis AG - Parkinson Disease Drug Product Portfolio and Specification
8.17.3 Novartis AG Performance Analysis (2020-2026)
8.17.4 Novartis AG Business and Markets Served
8.17.5 Novartis AG Recent Developments
9 Global Parkinson Disease Drug Market Forecast by Product Type and End User (2026-2033)
9.1 Global Parkinson Disease Drug Market Forecast by Product Type (2026-2033)
9.1.1 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Decarboxylase Inhibitors (2026-2033)
9.1.2 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Dopamine Agonists (2026-2033)
9.1.3 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Monoamine Oxidase Type B (MAO-B) Inhibitor (2026-2033)
9.1.4 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Catechol-O-Methyltransferase (COMT) Inhibitors (2026-2033)
9.1.5 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2033)
9.2 Global Parkinson Disease Drug Market Forecast by End User (2026-2033)
9.2.1 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Hospital Pharmacy (2026-2033)
9.2.2 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Retail Pharmacy (2026-2033)
9.2.3 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Online Pharmacy (2026-2033)
10 Global Parkinson Disease Drug Market Forecast by Geographic Region (2026-2033)
10.1 Global Parkinson Disease Drug Sales Volume and Revenue Forecast by Geographic Region (2026-2033)
10.2 North America Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.1 United States Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.2 Canada Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3 Europe Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.1 Germany Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.2 France Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.3 United Kingdom Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.4 Spain Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.5 Russia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.6 Poland Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4 Asia Pacific Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.1 China Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.2 Japan Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.3 South Korea Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.4 Southeast Asia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.5 India Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.6 Australia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5 Latin America Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.1 Mexico Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.2 Brazil Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6 Middle East and Africa Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.1 GCC Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.2 South Africa Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer
1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Parkinson Disease Drug Market Size
1.3 Market Segmentation
1.4 Regulatory Environment
2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Parkinson Disease Drug Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Parkinson Disease Drug Business Mode and Production Process
2.3.1 Parkinson Disease Drug Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Parkinson Disease Drug Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Parkinson Disease Drug
2.4.2 Raw Material Cost of Parkinson Disease Drug
2.4.3 Labor Cost of Parkinson Disease Drug
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis
3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War
4 Market Competitive Landscape
4.1 Global Parkinson Disease Drug Revenue and Market Share by Manufacturer (2020-2026)
4.2 Global Parkinson Disease Drug Sales Volume and Market Share by Manufacturer (2020-2026)
4.3 Global Parkinson Disease Drug Price by Manufacturer (2020-2026)
4.4 Parkinson Disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Parkinson Disease Drug, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Parkinson Disease Drug, Product Offered and Application
4.7 Parkinson Disease Drug Market Competitive Situation and Trends
4.7.1 Parkinson Disease Drug Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Parkinson Disease Drug Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans
5 Global Parkinson Disease Drug Market Historical Development by Geographic Region (2020-2026)
5.1 Global Parkinson Disease Drug Market Historical Sales Volume by Geographic Region (2020-2026)
5.2 Global Parkinson Disease Drug Market Historical Revenue by Geographic Region (2020-2026)
5.3 North America Parkinson Disease Drug Market Status by Country (2020-2026)
5.3.1 North America Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.3.2 North America Parkinson Disease Drug Revenue by Country (2020-2026)
5.3.3 United States Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.3.4 Canada Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4 Europe Parkinson Disease Drug Market Status by Country (2020-2026)
5.4.1 Europe Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.4.2 Europe Parkinson Disease Drug Revenue by Country (2020-2026)
5.4.3 Germany Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.4 France Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.5 United Kingdom Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.6 Spain Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.7 Russia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.4.8 Poland Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5 Asia Pacific Parkinson Disease Drug Market Status by Country (2020-2026)
5.5.1 Asia Pacific Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.5.2 Asia Pacific Parkinson Disease Drug Revenue by Country (2020-2026)
5.5.3 China Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.4 Japan Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.5 South Korea Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.6 Southeast Asia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.7 India Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.5.8 Australia Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.6 Latin America Parkinson Disease Drug Market Status by Country (2020-2026)
5.6.1 Latin America Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.6.2 Latin America Parkinson Disease Drug Revenue by Country (2020-2026)
5.6.3 Mexico Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.6.4 Brazil Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.7 Middle East and Africa Parkinson Disease Drug Market Status by Country (2020-2026)
5.7.1 Middle East and Africa Parkinson Disease Drug Sales Volume by Country (2020-2026)
5.7.2 Middle East and Africa Parkinson Disease Drug Revenue by Country (2020-2026)
5.7.3 GCC Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
5.7.4 South Africa Parkinson Disease Drug Sales Volume, Revenue and Growth (2020-2026)
6 Global Parkinson Disease Drug Market Historical Development by Product Type (2020-2026)
6.1 Parkinson Disease Drug Definition by Type
6.2 Global Parkinson Disease Drug Historical Sales Volume by Product Type (2020-2026)
6.3 Global Parkinson Disease Drug Historical Revenue by Product Type (2020-2026)
6.4 Global Parkinson Disease Drug Historical Price by Product Type (2020-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2020-2026)
6.5.1 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Decarboxylase Inhibitors (2020-2026)
6.5.2 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Dopamine Agonists (2020-2026)
6.5.3 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Monoamine Oxidase Type B (MAO-B) Inhibitor (2020-2026)
6.5.4 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Catechol-O-Methyltransferase (COMT) Inhibitors (2020-2026)
6.5.5 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Others (2020-2026)
7 Global Parkinson Disease Drug Market Historical Development by End User (2020-2026)
7.1 Downstream Market Overview
7.2 Global Parkinson Disease Drug Historical Sales Volume by End User (2020-2026)
7.3 Global Parkinson Disease Drug Historical Revenue by End User (2020-2026)
7.4 Global Parkinson Disease Drug Historical Price by End User (2020-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2020-2026)
7.5.1 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Hospital Pharmacy (2020-2026)
7.5.2 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Retail Pharmacy (2020-2026)
7.5.3 Global Parkinson Disease Drug Historical Sales Volume, Revenue and Growth Rate of Online Pharmacy (2020-2026)
8 Leading Companies Profiles
8.1 Sanofi S.A.
8.1.1 Sanofi S.A. Corporation Information
8.1.2 Sanofi S.A. - Parkinson Disease Drug Product Portfolio and Specification
8.1.3 Sanofi S.A. Performance Analysis (2020-2026)
8.1.4 Sanofi S.A. Business and Markets Served
8.1.5 Sanofi S.A. Recent Developments
8.2 Lundbeck A/S
8.2.1 Lundbeck A/S Corporation Information
8.2.2 Lundbeck A/S - Parkinson Disease Drug Product Portfolio and Specification
8.2.3 Lundbeck A/S Performance Analysis (2020-2026)
8.2.4 Lundbeck A/S Business and Markets Served
8.2.5 Lundbeck A/S Recent Developments
8.3 Impax Laboratories, Inc.
8.3.1 Impax Laboratories, Inc. Corporation Information
8.3.2 Impax Laboratories, Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.3.3 Impax Laboratories, Inc. Performance Analysis (2020-2026)
8.3.4 Impax Laboratories, Inc. Business and Markets Served
8.3.5 Impax Laboratories, Inc. Recent Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Teva Pharmaceutical Industries Ltd. Corporation Information
8.4.2 Teva Pharmaceutical Industries Ltd. - Parkinson Disease Drug Product Portfolio and Specification
8.4.3 Teva Pharmaceutical Industries Ltd. Performance Analysis (2020-2026)
8.4.4 Teva Pharmaceutical Industries Ltd. Business and Markets Served
8.4.5 Teva Pharmaceutical Industries Ltd. Recent Developments
8.5 GlaxoSmithKline plc
8.5.1 GlaxoSmithKline plc Corporation Information
8.5.2 GlaxoSmithKline plc - Parkinson Disease Drug Product Portfolio and Specification
8.5.3 GlaxoSmithKline plc Performance Analysis (2020-2026)
8.5.4 GlaxoSmithKline plc Business and Markets Served
8.5.5 GlaxoSmithKline plc Recent Developments
8.6 C.H. Boehringer Sohn AG & Ko. KG
8.6.1 C.H. Boehringer Sohn AG & Ko. KG Corporation Information
8.6.2 C.H. Boehringer Sohn AG & Ko. KG - Parkinson Disease Drug Product Portfolio and Specification
8.6.3 C.H. Boehringer Sohn AG & Ko. KG Performance Analysis (2020-2026)
8.6.4 C.H. Boehringer Sohn AG & Ko. KG Business and Markets Served
8.6.5 C.H. Boehringer Sohn AG & Ko. KG Recent Developments
8.7 ACADIA Pharmaceuticals Inc.
8.7.1 ACADIA Pharmaceuticals Inc. Corporation Information
8.7.2 ACADIA Pharmaceuticals Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.7.3 ACADIA Pharmaceuticals Inc. Performance Analysis (2020-2026)
8.7.4 ACADIA Pharmaceuticals Inc. Business and Markets Served
8.7.5 ACADIA Pharmaceuticals Inc. Recent Developments
8.8 Merck & Co., Inc.
8.8.1 Merck & Co., Inc. Corporation Information
8.8.2 Merck & Co., Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.8.3 Merck & Co., Inc. Performance Analysis (2020-2026)
8.8.4 Merck & Co., Inc. Business and Markets Served
8.8.5 Merck & Co., Inc. Recent Developments
8.9 Medtronic plc
8.9.1 Medtronic plc Corporation Information
8.9.2 Medtronic plc - Parkinson Disease Drug Product Portfolio and Specification
8.9.3 Medtronic plc Performance Analysis (2020-2026)
8.9.4 Medtronic plc Business and Markets Served
8.9.5 Medtronic plc Recent Developments
8.10 Abbvie Inc
8.10.1 Abbvie Inc Corporation Information
8.10.2 Abbvie Inc - Parkinson Disease Drug Product Portfolio and Specification
8.10.3 Abbvie Inc Performance Analysis (2020-2026)
8.10.4 Abbvie Inc Business and Markets Served
8.10.5 Abbvie Inc Recent Developments
8.11 Homann-La Roche Ltd
8.11.1 Homann-La Roche Ltd Corporation Information
8.11.2 Homann-La Roche Ltd - Parkinson Disease Drug Product Portfolio and Specification
8.11.3 Homann-La Roche Ltd Performance Analysis (2020-2026)
8.11.4 Homann-La Roche Ltd Business and Markets Served
8.11.5 Homann-La Roche Ltd Recent Developments
8.12 Pzer, Inc.
8.12.1 Pzer, Inc. Corporation Information
8.12.2 Pzer, Inc. - Parkinson Disease Drug Product Portfolio and Specification
8.12.3 Pzer, Inc. Performance Analysis (2020-2026)
8.12.4 Pzer, Inc. Business and Markets Served
8.12.5 Pzer, Inc. Recent Developments
8.13 F. Hoffmann-La Roche AG
8.13.1 F. Hoffmann-La Roche AG Corporation Information
8.13.2 F. Hoffmann-La Roche AG - Parkinson Disease Drug Product Portfolio and Specification
8.13.3 F. Hoffmann-La Roche AG Performance Analysis (2020-2026)
8.13.4 F. Hoffmann-La Roche AG Business and Markets Served
8.13.5 F. Hoffmann-La Roche AG Recent Developments
8.14 Vertical Pharmaceuticals, LLC
8.14.1 Vertical Pharmaceuticals, LLC Corporation Information
8.14.2 Vertical Pharmaceuticals, LLC - Parkinson Disease Drug Product Portfolio and Specification
8.14.3 Vertical Pharmaceuticals, LLC Performance Analysis (2020-2026)
8.14.4 Vertical Pharmaceuticals, LLC Business and Markets Served
8.14.5 Vertical Pharmaceuticals, LLC Recent Developments
8.15 Orion Pharma
8.15.1 Orion Pharma Corporation Information
8.15.2 Orion Pharma - Parkinson Disease Drug Product Portfolio and Specification
8.15.3 Orion Pharma Performance Analysis (2020-2026)
8.15.4 Orion Pharma Business and Markets Served
8.15.5 Orion Pharma Recent Developments
8.16 UCB S.A
8.16.1 UCB S.A Corporation Information
8.16.2 UCB S.A - Parkinson Disease Drug Product Portfolio and Specification
8.16.3 UCB S.A Performance Analysis (2020-2026)
8.16.4 UCB S.A Business and Markets Served
8.16.5 UCB S.A Recent Developments
8.17 Novartis AG
8.17.1 Novartis AG Corporation Information
8.17.2 Novartis AG - Parkinson Disease Drug Product Portfolio and Specification
8.17.3 Novartis AG Performance Analysis (2020-2026)
8.17.4 Novartis AG Business and Markets Served
8.17.5 Novartis AG Recent Developments
9 Global Parkinson Disease Drug Market Forecast by Product Type and End User (2026-2033)
9.1 Global Parkinson Disease Drug Market Forecast by Product Type (2026-2033)
9.1.1 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Decarboxylase Inhibitors (2026-2033)
9.1.2 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Dopamine Agonists (2026-2033)
9.1.3 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Monoamine Oxidase Type B (MAO-B) Inhibitor (2026-2033)
9.1.4 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Catechol-O-Methyltransferase (COMT) Inhibitors (2026-2033)
9.1.5 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2033)
9.2 Global Parkinson Disease Drug Market Forecast by End User (2026-2033)
9.2.1 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Hospital Pharmacy (2026-2033)
9.2.2 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Retail Pharmacy (2026-2033)
9.2.3 Global Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth Rate of Online Pharmacy (2026-2033)
10 Global Parkinson Disease Drug Market Forecast by Geographic Region (2026-2033)
10.1 Global Parkinson Disease Drug Sales Volume and Revenue Forecast by Geographic Region (2026-2033)
10.2 North America Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.1 United States Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.2.2 Canada Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3 Europe Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.1 Germany Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.2 France Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.3 United Kingdom Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.4 Spain Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.5 Russia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.3.6 Poland Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4 Asia Pacific Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.1 China Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.2 Japan Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.3 South Korea Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.4 Southeast Asia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.5 India Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.4.6 Australia Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5 Latin America Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.1 Mexico Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.5.2 Brazil Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6 Middle East and Africa Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.1 GCC Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
10.6.2 South Africa Parkinson Disease Drug Sales Volume, Revenue Forecast and Growth (2026-2033)
11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer
Our Clients
